Demant: Implants Divestiture to Cochlear Provisionally Challenged, but We Anticipate It Will Proceed
Narrow-moat Demant DEMANT announced that the U.K. Competition and Markets Authority’s provisional finding (prior to the final report in early June) is that the divestment of Oticon Medical to Cochlear ...
Cochlear turns life-changing hearing implants into serious stock-market power. But is this low-key Aussie giant actually worth your money, or is the hype louder than the results?
Cochlear has updated investors following the release of its FY 2024 results and guidance for FY 2025, highlighting solid implant demand and growing services revenue in a competitive global hearing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results